Genmab A/S (GMAB)
Stock Price:
$35.87 USD
-0.18 (-0.50%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $36.88 +1.01 (2.82%) Aug 11, 5:43 PM
Key Info
| Market Cap |
23.39B |
| Revenue (ttm) |
845.42M |
| Net Income (ttm) |
341.26M |
| Shares Out |
651.83M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
31.75 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$35.87 |
| Previous Close |
$36.05 |
| Change ($) |
-0.18 |
| Change (%) |
-0.50% |
| Day's Open |
36.71 |
| Day's Range |
35.61 - 36.86 |
| Day's Volume |
634,022 |
| 52-Week Range |
24.13 - 36.86 |
More Stats
| Market Cap |
23.39B |
| Enterprise Value |
21.69B |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
651.83M |
| Float |
642.65M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
0.30 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
0.82% |
| Payout Ratio |
n/a |
| Shares Short |
889,516 |
| Short Ratio |
0.72 |
| Short % of Float |
n/a |
| Beta |
0.50 |
| PE Ratio |
n/a |
| Forward PE |
31.75 |
| P/FCF Ratio |
122.18 |
| PS Ratio |
27.67 |
| PB Ratio |
10.37 |
| Revenue |
845.42M |
| Operating Income |
415.62M |
| Net Income |
341.26M |
| Free Cash Flow |
191.43M |
| Net Cash |
1.70B |
| Net Cash / Share |
2.61 |
| Gross Margin |
100.00% |
| Operating Margin |
49.16% |
| Profit Margin |
40.40% |
| FCF Margin |
22.64% |
| ROA |
14.22% |
| ROE |
20.98% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (22)
| Buy |
12 |
| Overweight |
1 |
| Hold |
6 |
| Underweight |
1 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$33.43*
(-6.80% downside)
Low
20.7
Current: $35.87
High
40.0
Target: 33.43
*Average 12-month USD price target from 20 stock analysts.
Financial Performance
Financial numbers in millions DKK.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 5,366 | 3,025 | 2,365 |
| Revenue Growth | 77.39% | 27.91% | - |
| Gross Profit | 5,366 | 3,025 | 2,365 |
| Operating Income | 2,638 | 1,380 | 1,344 |
| Net Income | 2,166 | 1,472 | 1,104 |
| Shares Outstanding | 64.30 | 64.30 | - |
| Earnings Per Share | 3.40 | 2.37 | 1.78 |
| EPS Growth | 43.4% | 33.54% | - |
| Operating Cash Flow | 1,326 | 1,015 | 1,589 |
| Capital Expenditures | -111 | -478 | -89.00 |
| Free Cash Flow | 1,215 | 537 | 1,500 |
| Cash & Equivalents | 10,971 | 6,106 | 5,423 |
| Total Debt | 181 | - | - |
| Net Cash / Debt | 10,790 | 6,106 | 5,423 |
| Assets | 15,144 | 8,461 | 6,603 |
| Liabilities | 1,096 | 447 | 331 |
| Book Value | 14,048 | 8,014 | 6,272 |
Numbers in millions DKK, except per-share numbers.
Company Details
| Full Name |
Genmab A/S |
| Country |
Denmark |
| Employees |
579 |
| CEO |
Jan G. J. van de Winkel |
Stock Information
| Ticker Symbol |
GMAB |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: GMAB |
Description
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.